open access
VTD in comparison with VCD does not affect stem cell yields with G-CSF only mobilization
Affiliations- Department of Hematology, Division of Internal Medicine, University Medical Center Ljubljana, Slovenia
open access
Abstract
Triplet induction regimens are standard of care for newly diagnosed transplant eligible multiple myeloma patients. The combinations of bortezomib and dexamethasone with either cyclophosphamide (VCD) or thalidomide (VTD) are widely used. There are no data available on the impact of the two regimens on stem cell harvest by using G-CSF only mobilization. In this study, we retrospectively analyzed data from our national registry. The outcome measures were mobilization failure, CD34+ cell counts on collection day, number of apheresis procedures, and the number of collected cells. Overall, 72 patients were treated with either VCD or VTD. The mobilization failure rates were 7% and 9% ( = 0.771) and the total number of collected stem cells were 7.0 × 10 and 6.7 × 10 per kg body weight ( = 0.710) for VCD and VTD, respectively. We found no statistically significant difference between the treatment groups in the outcome measures. The addition of thalidomide to bortezomib and dexamethasone (VTD) does not adversely affect stem cell harvest in patients mobilized with G-CSF only.
Abstract
Triplet induction regimens are standard of care for newly diagnosed transplant eligible multiple myeloma patients. The combinations of bortezomib and dexamethasone with either cyclophosphamide (VCD) or thalidomide (VTD) are widely used. There are no data available on the impact of the two regimens on stem cell harvest by using G-CSF only mobilization. In this study, we retrospectively analyzed data from our national registry. The outcome measures were mobilization failure, CD34+ cell counts on collection day, number of apheresis procedures, and the number of collected cells. Overall, 72 patients were treated with either VCD or VTD. The mobilization failure rates were 7% and 9% ( = 0.771) and the total number of collected stem cells were 7.0 × 10 and 6.7 × 10 per kg body weight ( = 0.710) for VCD and VTD, respectively. We found no statistically significant difference between the treatment groups in the outcome measures. The addition of thalidomide to bortezomib and dexamethasone (VTD) does not adversely affect stem cell harvest in patients mobilized with G-CSF only.
Keywords
myeloma; HSCT; stem cell transplantation; mobilization; G-CSF
About this articleTitle
VTD in comparison with VCD does not affect stem cell yields with G-CSF only mobilization
Journal
Issue
Pages
42-46
Published online
2020-03-01
Page views
171
Article views/downloads
217
DOI
10.2478/ahp-2020-0009
Bibliographic record
Acta Haematol Pol 2020;51(1):42-46.
Keywords
myeloma
HSCT
stem cell transplantation
mobilization
G-CSF
Authors
Matevz Skerget
Barbara Skopec
Matjaz Sever